AZATHIOPRINE-50 TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

AZATHIOPRINE

Saadav alates:

PRO DOC LIMITEE

ATC kood:

L04AX01

INN (Rahvusvaheline Nimetus):

AZATHIOPRINE

Annus:

50MG

Ravimvorm:

TABLET

Koostis:

AZATHIOPRINE 50MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

IMMUNOSUPPRESSIVE AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0101830001; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2023-07-10

Toote omadused

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AZATHIOPRINE-50
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
PRO DOC LTÉE
Date of Revision:
2925, Boul. Industriel,
February 11, 2020
Laval, Quebec
H7L 3W9
Submission Control No.: 235658
_AZATHIOPRINE-50 Product Monograph _
_ _
Page 2 of 29
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
9
DRUG INTERACTIONS
............................................................................................................................
11
DOSAGE AND ADMINISTRATION
........................................................................................................
12
OVERDOSAGE
..........................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
13
STORAGE AND STABILITY
....................................................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................